INTRODUCTION: Worldwide, cervical cancer is the third most common cancer in women. In the UK, incidence fell after the introduction of the cervical screening programme, to the current level of approximately 2334 women in 2008, with a mortality to incidence ratio of 0.33. Survival ranges from almost 100% 5-year disease-free survival for treated stage Ia disease to 5-15% in stage IV disease. Survival is also influenced by tumour bulk, age, and comorbid conditions. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent cervical cancer? What are the effects of interventions to manage early-stage cervical cancer? What are the effects of interventions to manage bulky early-stage cervical cancer? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 14 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: human papillomavirus (HPV) vaccine for preventing cervical cancer; conisation of the cervix for microinvasive carcinoma (stage Ia1), conisation of the cervix plus lymphadenectomy (stage Ia2 and low-volume, good prognostic factor stage Ib), radical trachelectomy for low-volume stage Ib disease, neoadjuvant chemotherapy, radiotherapy, chemoradiotherapy, or different types of hysterectomy versus each other for treating early-stage and bulky early-stage cervical cancer.
INTRODUCTION: Worldwide, cervical cancer is the third most common cancer in women. In the UK, incidence fell after the introduction of the cervical screening programme, to the current level of approximately 2334 women in 2008, with a mortality to incidence ratio of 0.33. Survival ranges from almost 100% 5-year disease-free survival for treated stage Ia disease to 5-15% in stage IV disease. Survival is also influenced by tumour bulk, age, and comorbid conditions. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent cervical cancer? What are the effects of interventions to manage early-stage cervical cancer? What are the effects of interventions to manage bulky early-stage cervical cancer? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 14 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: human papillomavirus (HPV) vaccine for preventing cervical cancer; conisation of the cervix for microinvasive carcinoma (stage Ia1), conisation of the cervix plus lymphadenectomy (stage Ia2 and low-volume, good prognostic factor stage Ib), radical trachelectomy for low-volume stage Ib disease, neoadjuvant chemotherapy, radiotherapy, chemoradiotherapy, or different types of hysterectomy versus each other for treating early-stage and bulky early-stage cervical cancer.
Authors: J E Sardi; A Giaroli; C Sananes; M Ferreira; A Soderini; A Bermudez; L Snaidas; S Vighi; N Gomez Rueda; G di Paola Journal: Gynecol Oncol Date: 1997-10 Impact factor: 5.482
Authors: J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz Journal: J Pathol Date: 1999-09 Impact factor: 7.996
Authors: Luisa L Villa; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault; Anna R Giuliano; Cosette M Wheeler; Laura A Koutsky; Christian Malm; Matti Lehtinen; Finn Egil Skjeldestad; Sven-Eric Olsson; Margareta Steinwall; Darron R Brown; Robert J Kurman; Brigitte M Ronnett; Mark H Stoler; Alex Ferenczy; Diane M Harper; Gretchen M Tamms; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Frank J Taddeo; Kathrin U Jansen; Mark T Esser; Heather L Sings; Alfred J Saah; Eliav Barr Journal: Lancet Oncol Date: 2005-05 Impact factor: 41.316
Authors: F Landoni; A Maneo; A Colombo; F Placa; R Milani; P Perego; G Favini; L Ferri; C Mangioni Journal: Lancet Date: 1997-08-23 Impact factor: 79.321
Authors: T C Chang; C H Lai; J H Hong; S Hsueh; K G Huang; H H Chou; C J Tseng; C S Tsai; J T Chang; C T Lin; H H Chang; P J Chao; K K Ng; S G Tang; Y K Soong Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: John M Kirwan; Paul Symonds; John A Green; Jayne Tierney; Mandy Collingwood; Christopher J Williams Journal: Radiother Oncol Date: 2003-09 Impact factor: 6.280
Authors: H M Keys; B N Bundy; F B Stehman; L I Muderspach; W E Chafe; C L Suggs; J L Walker; D Gersell Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245